Company news
Precigen, Inc. (NASDAQ:PGEN) news
Precigen, Inc. news releases on 6ix. Latest, Sep 21, 2026: Precigen Receives FDA Platform Technology Designation for AdenoVerse Platform
Press releases & updates
Precigen Receives FDA Platform Technology Designation for AdenoVerse Platform
September 21, 2026
Precigen Reports Second Quarter 2026 Financial Results Highlighted by Accelerating PAPZIMEOS Revenue Growth
August 4, 2026
Precigen to Announce Second Quarter 2026 Financial Results and Provide Business Updates on August 4
July 21, 2026
Precigen Gains Advantage as PAPZIMEOS Granted Orphan Drug Exclusivity by FDA; Long-Term Data From Clinical Study Encouraging
June 14, 2026
Precigen and the Recurrent Respiratory Papillomatosis Foundation Recognize International RRP Awareness Day by Elevating Patient and Community Voices
June 11, 2026
Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years
May 30, 2026
Precigen Receives Orphan Drug Exclusivity for PAPZIMEOS (zopapogene imadenovec-drba) in the United States
May 26, 2026
Precigen to Participate in Fireside Chats with J.P. Morgan and at the Goldman Sachs 47th Annual Global Healthcare Conference
May 26, 2026
Precigen Reports First Quarter 2026 Financial Results and Business Updates
May 13, 2026
Precigen to Announce First Quarter 2026 Financial Results and Provide Business Updates on May 13
May 7, 2026
Precigen to Participate in a Fireside Chat with H.C. Wainwright on March 31
March 29, 2026
Precigen Reports Full Year 2025 Financial Results and Business Updates
March 24, 2026
Precigen to Announce Full Year 2025 Financial Results and Provide Business Updates on March 25
March 10, 2026
New Expert Consensus Published in The Laryngoscope Recommends PAPZIMEOS (zopapogene imadenovec) as the New Standard of Care First-Line Treatment for Adults with Recurrent Respiratory Papillomatosis
January 20, 2026
Precigen Showcases Rapid Commercialization Momentum and Growing Market Adoption of First-and-Only FDA-Approved Therapy for RRP at the 44th Annual J.P. Morgan Healthcare Conference
January 11, 2026
Precigen to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 4, 2026
Precigen Reports Third Quarter 2025 Financial Results and Business Updates
November 12, 2025
Precigen to Announce Third Quarter 2025 Financial Results and Provide Business Updates on November 13
November 5, 2025
Precigen Announces Long-Term Follow-Up Results Highlighting Ongoing Durable Complete Responses after Treatment with PAPZIMEOS, the First and Only FDA-approved Therapy for Adults with Recurrent Respiratory Papillomatosis
October 12, 2025
EVERSANA Named by Precigen for U.S. Commercialization of PAPZIMEOS
September 11, 2025
Precigen Announces Up to $125 Million Non-Dilutive Financing
September 1, 2025
Precigen to Participate in Upcoming Virtual Fireside Chats Hosted by Cantor and H.C. Wainwright
August 24, 2025
Precigen Announces Full FDA Approval of PAPZIMEOS (zopapogene imadenovec-drba), the First and Only Approved Therapy for the Treatment of Adults with Recurrent Respiratory Papillomatosis
August 14, 2025
Precigen Reports First Quarter 2025 Financial Results and Business Updates
May 13, 2025
Precigen and Recurrent Respiratory Papillomatosis Foundation to Host the 2025 International RRP Awareness Day on June 11th
April 15, 2025
Precigen Reports Full Year 2024 Financial Results and Business Updates
March 18, 2025
Precigen to Announce Full Year 2024 Financial Results and Provide Business Updates on March 19th
March 12, 2025
FDA Grants Priority Review to Precigen's BLA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis with PDUFA Target Action Date Set for August 27, 2025
February 24, 2025
Precigen to Present Plans for Realizing Commercial Vision for PRGN-2012 at the 43rd Annual J.P. Morgan Healthcare Conference
January 12, 2025
Precigen to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 8, 2025
Precigen Completes Submission of BLA with Request for Priority Review to the FDA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis
December 29, 2024
Precigen Announces $79.0 Million Private Placement Offering of Convertible Preferred Stock
December 26, 2024
Precigen Reports Third Quarter 2024 Financial Results and Business Updates
November 13, 2024
Precigen to Participate in the Stifel 2024 Healthcare Conference
November 11, 2024
Precigen to Participate in the 2024 Cantor Global Healthcare Conference
September 15, 2024
Precigen Reports Second Quarter and First Half 2024 Financial Results and Business Updates
August 13, 2024
Precigen to Announce Second Quarter and First Half 2024 Financial Results on August 14th
August 8, 2024
Precigen Announces Pricing of $30.0 Million Public Offering of Common Stock
August 6, 2024
Precigen Strategically Prioritizes Portfolio to Focus on First Potential Gene Therapy Launch
August 5, 2024
Precigen Announces Proposed $30 Million Public Offering of Common Stock
August 5, 2024
Precigen Appoints Phil Tennant as Chief Commercial Officer to Spearhead First Potential Gene Therapy Launch
July 22, 2024
Precigen Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More than Half of Patients Achieved Complete Response
June 2, 2024
Precigen to Host a Webcast on June 3rd to Detail Pivotal Study Results of PRGN-2012 in Recurrent Respiratory Papillomatosis Presented at the 2024 ASCO Annual Meeting
May 22, 2024
Precigen Reports First Quarter 2024 Financial Results and Business Updates
May 13, 2024
Precigen to Announce First Quarter 2024 Financial Results on May 14th and Host a Conference Call on June 3rd following the Late-breaking Oral Presentation for PRGN-2012 at the 2024 ASCO Annual Meeting
May 7, 2024
Precigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Patients with Recurrent Respiratory Papillomatosis at the 2024 ASCO Annual Meeting
April 23, 2024
Precigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day on June 11th
March 27, 2024
Precigen Reports Full Year 2023 Financial Results and Business Updates
March 18, 2024
Precigen to Participate in a Fireside Chat Hosted by Cantor Fitzgerald to Discuss PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis
March 11, 2024
Precigen to Announce Fourth Quarter and Full Year 2023 Financial Results on March 19th
March 4, 2024